00_RadBio_Programme_Paris_September 2017.pdf |
1 |
0_MJ_Intro_Paris17_WS |
4-5 |
1_VG_Introduction Paris 2017 |
46 |
2_2017_Koritzinsky_Hallmarks of Cancer |
66-67 |
3_2017_Koritzinsky_Cell Death |
136-137 |
4 _cell_surv_Coppes 2017 Paris |
214-215 |
5_MJ_Models_Paris17_WS |
292-293 |
6_WD_Pathogenesis of NT effects |
346-347 |
7_KH_Clinical side effects |
428-429 |
8_MJ_LQapproach_Paris17_WS |
558-559 |
9_2017_Koritzinsky_MolBasisDNAdamageResponse |
612-613 |
10 _WD_NT radiosensitivity and fractionation |
674-675 |
11_WD_NT overall treatment time |
718-719 |
12_VG_HFAF Paris 2017 |
786 |
13_MJ_LQpractice_Paris17_WS |
808-809 |
14_MJ_KH_LQ models examples of calculations |
844-845 |
15 _WD_Volume effects in RT |
912-913 |
16_MK_HypoxiaTumorMicroenvironment |
990-991 |
17_KH_Hypoxia modification |
1076-1077 |
18_MJ_DoseRespRels_Paris17_WS |
1198-1199 |
19_MJ_LETandRBE_Paris17_WS |
1258-1259 |
19_VG_KH_Excercise Lower GU |
1314-1315 |
20_MK_Biological_modifiers_preclinical |
1408-1409 |
21_KH_Biological response modifiers |
1490-1491 |
22_RC_Biological modifiers of normal tissue effects Paris 2017 |
1590-1591 |
23_VG RT_CH Paris 2017 |
1670 |
24_RC_Retreatement tolerance Paris 2017 |
1688-1689 |
25_VG Funct Imag Paris 2017 |
1770 |
26_KH_Tumor growth and response to irradiation |
1792-1793 |
27_RC_Dose-rate & brachyther paris 2017 |
1898-1899 |
28_VG_Particles in RT |
1958 |
29_MJ_RadnInducedMalig_Paris17_WS |
1988-1989 |